There may be several reasons for the failure to obtain the anticancer effect of the FFAR2 agonist in mice, i.e. too low a dose of the used compound and infrequent solution injection, as well as improper route of administration, mouse strain, and CRC model. Here, FFAR2 is linked to colorectal carcinoma.